Evidence map›Paper›PMID 40243993›Full record

ReviewInternational journal of molecular sciences2025

Double Strike in Chronic Lymphocytic Leukemia-The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice.

Przemyslaw Zygmunciak, Hanna Dancewicz, Katarzyna Stróżna, Olga Błażowska, Krzysztof Bieliński, Tadeusz Robak, Bartosz Puła

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Przemyslaw ZygmunciakFaculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland.ORCID 0009-0004-1404-7544
Hanna DancewiczFaculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland.ORCID 0009-0001-1596-2232
Katarzyna StróżnaFaculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland.
Olga BłażowskaFaculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland.ORCID 0009-0003-6989-3062
Krzysztof BielińskiFaculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland.ORCID 0009-0004-3082-5254
Tadeusz RobakDepartment of Hematology, Medical University of Lodz, 93-510 Lodz, Poland.ORCID 0000-0002-3411-6357
Bartosz PułaDepartment of Hematology, Medical University of Lodz, 93-510 Lodz, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the recent 2024 ESMO guidelines, the combination of venetoclax and ibrutinib was listed as one of the first-line treatment options for CLL patients. These drugs were first-in-class medicines that revolutionized CLL management, extending patients' overall survival even in cases refractory to immunochemotherapy. However, since the approval of both compounds, more and more Bruton Tyrosine Kinase inhibitors (BTKis) and B-cell lymphoma 2 inhibitors (BCL2is) have been discovered. Their efficacy and safety are the reasons for their use in monotherapy among both treatment-naïve and relapsed patients with CLL. Currently, several ongoing clinical trials are investigating the rationale for the combination of BCL2is and BTKis. In this review, we discuss the recent advancements in the field of co-therapy with BTKis and BCL2is.

Indexed as

Agammaglobulinaemia Tyrosine KinaseAntineoplastic Combined Chemotherapy ProtocolsLeukemia, Lymphocytic, Chronic, B-CellProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2AdenineBridged Bicyclo Compounds, HeterocyclicHumansPiperidinesSulfonamidesAdenineAgammaglobulinaemia Tyrosine KinaseBCL2 protein, humanBridged Bicyclo Compounds, HeterocyclicBTK protein, humanibrutinibPiperidinesProtein Kinase InhibitorsProto-Oncogene Proteins c-bcl-2SulfonamidesvenetoclaxB-cell lymphoma 2 inhibitorsBruton kinase inhibitorschronic lymphocytic leukemiatherapy

Identifiers

PMID40243993
PMCPMC11989886

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.